Svetlana Selivanova is radiochemist and subject-matter expert in radiopharmaceutical sciences. She earned her BSc in chemistry (with physics and mathematics; Prof. Natalia Essina) and MSc in chemistry (Prof. Aslan Tsivadze) from Peoples’ Friendship University of Russia, and PhD in radiopharmaceutical chemistry and radiobiology from Université de Sherbrooke (Prof. Johan van Lier, Prof. Svetlana Kudrevich). After several years of postdoctoral research at Clinical Research Centre Étienne-Le-Bel (Prof. Francois Benard) and at ETH Zurich (Prof. August Schubiger, Prof. Simon Ametamey), she was promoted as a group leader and deputy head at the Centre for Radiopharmaceutical Sciences at ETH Zurich. In 2012, she was invited by CRCHU de Sherbrooke to lead the radiopharmaceutical development of commercial-scale production of Tc-99m medical isotope by cyclotron. She was recruited by CHU de Quebec – Université Laval in 2017 to set up new cyclotron and radiopharmaceutical facility. Internationally, she is a member of several professional societies, is active as expert for the European Commission Research Executive Agency, and serves as Director and Treasurer on the SNMMI Radiopharmaceutical Sciences Council Board of Directors.
Dr. Selivanova has extensive experience in cyclotron production of medical isotopes, nuclear and radiochemistry, radiopharmacology, and development of radiopharmaceuticals at all stages from early R&D to first-in-human clinical trials and cGMP. Her research interests are multidisciplinary and encompass, at large, development and application of small-molecule radiolabelled compounds for molecular imaging, therapy, and in support of drug development. Radiolabelled compounds open fascinating opportunities for fundamental science and for clinical practice and have a range of applications in medical diagnostics, drug discovery, and assessment of therapeutic interventions. These molecules deliver information about body metabolism, receptors function or drug pharmacology and, thereby, enable in vivo study of normal and pathological biochemical processes and physiology on molecular as well as systemic level. As a member of the Oncology axis, Svetlana Selivanova is involved in several projects focused on innovative cancer theranostics and translational research.
1401, 18e rue
Pavillon Notre Dame
Canada G1L 1Z4
Data not available
Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.Journal Article
J Med Chem, 56 (12), pp. 4912-20, 2013, ISSN: 0022-2623.
Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors.Journal Article
Chem Biodivers, 10 (4), pp. 538-55, 2013, ISSN: 1612-1872.
Synthesis and biological evaluation of ¹⁸F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging.Journal Article
Eur J Med Chem, 70 , pp. 768-80, 2013, ISSN: 0223-5234.
Single-step radiofluorination of peptides using continuous flow microreactor.Journal Article
Org Biomol Chem, 10 (19), pp. 3871-4, 2012, ISSN: 1477-0520.
Radiofluorinated histamine H₃ receptor antagonist as a potential probe for in vivo PET imaging: radiosynthesis and pharmacological evaluation.Journal Article
Bioorg Med Chem, 20 (9), pp. 2889-96, 2012, ISSN: 0968-0896.
Synthesis and molecular structure of 4-methoxyphenyl-2'-pyrrolylthione and its rhenium complexJournal Article
Inorganica chim acta, 349 , pp. 58-64, 2003, ISSN: 0020-1693.
The synthesis and properties of new 2-pyrrolylthiones as chelating agents for transition metals and technetium.Journal Article
Bioorg Med Chem Lett, 11 (20), pp. 2697-9, 2001, ISSN: 0960-894X.
Synthesis and spectroscopic study of the zinc complex with tetracrown-substituted phthalocyaninesJournal Article
Russ J Inorg Chem, 43 (2), pp. 209-215, 1998, ISSN: 0036-0236.